| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114874 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
Jan, 2027
(3 years from now) | |
| US9493470 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| US11192897 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| US11384086 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9029533 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US11192895 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
Iclusig is owned by Takeda Pharms Usa.
Iclusig contains Ponatinib Hydrochloride.
Iclusig has a total of 6 drug patents out of which 0 drug patents have expired.
Iclusig was authorised for market use on 14 December, 2012.
Iclusig is available in tablet;oral dosage forms.
Iclusig can be used as a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for treating chronic myeloid leukemia, a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating chronic myeloid leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain, a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating chronic myeloid leukemia, a method of treating chronic myelogenous leukemia; a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for the treatment of leukemias; a method for treating acute lymphoblastic leukemia.
The generics of Iclusig are possible to be released after 12 December, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 18, 2023 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 14 December, 2012
Treatment: A method of treating chronic myelogenous leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the ...
Dosage: TABLET;ORAL
ICLUSIG family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic